PYC-001

DRUG2 trials

Sponsors

PYC Therapeutics

Conditions

Autosomal Dominant Optic AtrophyHereditary Optic AtrophiesKjer Optic AtrophyOPA1 Gene Mutation

Phase 1

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

Active, not recruitingNCT06461286

PYC TherapeuticsAutosomal Dominant Optic Atrophy, Hereditary Optic Atrophies, Kjer Optic Atrophy +1

Start: 2024-10-31End: 2029-11-01Target: 18Updated: 2026-09-17

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

RecruitingNCT06970106

PYC TherapeuticsAutosomal Dominant Optic Atrophy, Hereditary Optic Atrophies, Kjer Optic Atrophy +1

Start: 2025-09-30End: 2029-11-01Target: 24Updated: 2026-06-29